We receives advance assurance for EIS status in the United Kingdom
post-template-default,single,single-post,postid-10584,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Evolution Biotechnologies listed by OBN Ventures

Bedford, UK, July 20th 2020

Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, today reports that it has completed the registration process and has been listed on Oxford Business Network’s OBN Ventures Investment Platform at https://obn.envestry.com/.

Dr. David Harper, CEO of Evolution, said: “this is an important step forward in today’s difficult market, and we look forward to working with OBN Ventures to present this opportunity to a new group of investors”.

About OBN Ventures:

OBN Ventures Ltd (OBNV) is a wholly owned subsidiary of OBN (UK) Ltd, and offers a sophisticated FCA-approved on-line investment platform which is designed to bring a wide range of professional investors together with early-stage life sciences and related companies that in some instances are yet to achieve any revenues and in the majority of cases will not have reached the point of profitability. This platform is totally complementary in approach with OBN’s major investment conferences (BioTrinity® and BioSeed®) and offers the advantages of leveraging a wider range of investors and availability on a year-long basis. OBNV’s core strategy is to focus on early stage life sciences companies with strong intellectual property (‘IP’), and the potential for growth to £100m+ valuations or more, where the added value of OBNV/OBN may offer distinct advantage to investee companies.

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self-amplifying biological control for the house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document contains certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

Email: pr@evolutionbiotech.com
Website: www.evolutionbiotech.com

No Comments

Sorry, the comment form is closed at this time.